Tokai Pharmaceuticals Inc. (NASDAQ:TKAI) rose 2.6% during mid-day trading on Thursday . The company traded as high as $5.56 and last traded at $5.47, with a volume of 87,999 shares traded. The stock had previously closed at $5.33.

TKAI has been the subject of a number of recent analyst reports. Janney Montgomery Scott initiated coverage on Tokai Pharmaceuticals in a research report on Wednesday, April 6th. They set a “buy” rating for the company. Bank of America Corp. initiated coverage on Tokai Pharmaceuticals in a research report on Wednesday, April 6th. They set a “buy” rating and a $16.00 target price for the company. Finally, BMO Capital Markets initiated coverage on Tokai Pharmaceuticals in a research report on Monday, April 11th. They set an “outperform” rating and a $11.00 target price for the company. One analyst has rated the stock with a sell rating and five have given a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $18.00.

The firm’s market capitalization is $121.78 million. The company has a 50-day moving average price of $5.87 and a 200 day moving average price of $6.34.

Tokai Pharmaceuticals (NASDAQ:TKAI) last released its quarterly earnings results on Tuesday, May 10th. The biopharmaceutical company reported ($0.51) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.50) by $0.01. Equities research analysts anticipate that Tokai Pharmaceuticals Inc. will post ($2.00) EPS for the current year.

Tokai Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on developing and commercializing therapies for the treatment of prostate cancer and other hormonally-driven diseases. The Company’s lead drug candidate, galeterone, is an oral small molecule that utilizes the mechanistic pathways of second-generation androgen signaling inhibitors, while also introducing a third mechanism-androgen receptor degradation.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.